Five-year results of a prospective case series of accelerated hypofractionated whole breast radiation with concomitant boost to the surgical bed after conserving surgery for early breast cancer

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Cante, Domenico ^a   Franco, Pierfrancesco ^b   Sciacero, Piera ^a   Girelli, Giuseppe ^a   Marra, Anna Maria ^a   Pasquino, Massimo ^a   Russo, Giuliana ^a   Borca, Valeria Casanova ^a   Mondini, Guido ^a   Paino, Ovidio ^a   Barmasse, Roberto ^b   Tofani, Santi ^a   Numico, Gianmauro ^b   La Porta, Maria Rosa ^a   Ricardi, Umberto ^c  

^a Ivrea Community Hospital   (Italy)

^b Ospedale Regionale 'U Parini'   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Adjuvant whole breast radiotherapy; Breast cancer; Concomitant boost; Cosmesis; Hypofractionation; Simultaneous integrated boost

Indexed keywords

ACUTE TOXICITY; ADULT; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CASE STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SKIN TOXICITY; WHOLE BREAST RADIATION; BREAST TUMOR; COHORT ANALYSIS; EARLY DIAGNOSIS; MIDDLE AGED; MORTALITY; RADIATION RESPONSE; SEGMENTAL MASTECTOMY; TREATMENT OUTCOME;

ADULT; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84874397765     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0518-7     Document Type: Article

References (32)

1. Poortmans P. Evidence-based radiation oncology: breast cancer. Radiother Oncol. 2007;84:84-101.
2. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15 years survival: an overview of the randomized trials. Lancet. 2005;366:2087-106.
3. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Warlam-Rodenhuis CC, Pierart M, Colette L. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10 years results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25:3259-65.
4. Mannino M, Yarnold JR. Shorter fractionation schedules in breast cancer radiotherapy: clinical and economic implications. Eur J Cancer. 2009;45:730-1.
5. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:679-94.
6. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131-46.
7. Bantema-Joppe EJ, van der Laan HP, de Bock GH, Wijsman R, Dolsma WV, Busz DM, Langendijk JA, Maduro JH. Three-dimensional conformal hypofractionated simultaneous integrated boost in breast conserving therapy: results on local control and survival. Radiother Oncol. 2011;100:215-20.
8. Cante D, La Porta MR, Casanova-Borca, Sciacero P, Girelli G, Pasquino M, Franco P, Ozzello F. Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients. Breast J. 2011;17:586-93.
9. National Cancer Institute Cancer Therapy Evaluation Program. Common Toxicity Criteria for Adverse Events. 2012 Version 3.0. Available at http://ctep.cancer.gov. Accessed August 2012.
10. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341-6.
11. Rose MA, Olivotto IA, Cady B, Koufman C, Osteen R, Silver B, Recht A, Harris JR. Conservative surgery and radiation therapy for early stage breast cancer: long-term cosmetic results. Arch Surg. 1989;124:153-7.
12. Fayers PM, Aaronson NK, Bjordal K, Curan D, Groenvold M. On behalf of the EORTC quality of life study group. EORTC QLQ-C30 scoring manual (2nd ed.). Brussels: EORTC.
13. Coles CE, Brunt AM, Wheatley D, Mukesh MB, Yarnold JR. Breast radiotherapy: less is more ? Clin Oncol. 2013;25:127-34.
14. Holloway CL, Panet-Raymond V, Olivotto I. Hypofractionation should be the new 'standard' for radiation therapy after breast conserving surgery. Breast. 2010;19:163-7.
15. Harnett A. Fewer fractions of adjuvant external beam radiotherapy for early breast cancer are safe and effective and can now be the standard of care. Why the UK's NICE accepts fewer fractions as the standard of care for adjuvant radiotherapy in early breast cancer. Breast. 2010;19:159-62.
16. Lievens Y. Hypofractionated breast radiotherapy: financial and economic consequences. Breast. 2010;19:192-7.
17. Fowler JF. 21 years of biologically effective dose. Br J Radiol. 2010;83:554-68.
18. Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, Haviland J, Bentzen S, Owen R. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomized trial. Radiother Oncol. 2005;75:9-17.
19. The START Trialists' Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin P, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet Oncol. 2008;9:331-41.
20. The START Trialists' Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin P, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR. The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet. 2008;371:1098-107.
21. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, Shelley W, Grimard L, Bowen J, Lukka H, Perera F, Fyles A, Schneider K, Gulavita S, Freeman C. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513-20.
22. James ML, Lehman M, Hider PN, Jeffery M, Hickey BE, Francis DP. Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database Syst Rev. 2008;3:CD003860.
23. Romestaing P, Lehingue Y, Carrie C, Coquard R, Montbarbon X, Ardiet JM, Mamelle N, Gerard JP. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon. France J Clin Oncol. 1997;15:963-8.
24. Freedman GM, Anderson PR, Bleicher RJ, Litwin S, Li T, Swaby RF, Ma CM, Li J, Sigurdson ER, Watkins-Bruner D, Morrow M, Goldstein LJ. Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer. Int J Radiat Oncol Biol Phys. 2012;84:888-93.
25. Chadha M, Woode R, Sillanpaa J, Lucido D, Boolbol SK, Kirstein L, Osborne MP, Feldman S, Harrison LB. Early-stage breast cancer treated with 3-week accelerated whole-breast radiation therapy and concomitant boost. Int J Radiat Oncol Biol Phys. 2013 (in press); doi: 10.1016/j.ijrobp.2012.11.010.
26. Formenti SC, Gidea-Addeo D, Goldberg JD, Roses DF, Guth A, Rosenstein BS, DeWyngaert KJ. Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol. 2007;25:2236-42.
27. McDonald MW, Godette KD, Whitaker DJ, Davis LW, Johnstone PA. 3 years outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost. Int J Radiat Oncol Biol Phys. 2010;77:523-30.
28. Bantema-Joppe EJ, Schilstra C, de Bock GH, Dolsma WV, Busz DM, Langendijk JA, Maduro JH. Simultaneous integrated boost irradiation after breast-conserving surgery: physician-rated toxicity and cosmetic outcome at 30 months' follow up. Int J Radiat Oncol Biol Phys. 2012;83:e471-7.
29. Engel J, Kerr J, Schlesinger-Raab A, Sauer H, Holzel D. Quality of life following breast-conserving therapy or mastectomy: results of a 5 years prospective study. Breast J. 2004;10:223-31.
30. Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14:2756-68.
31. Coles C. Yarnold J-IMPORT Trials Management Group. The IMPORT trials are launched (September 2006). Clin Oncol. 2006;18:587-90.
32. Higher-dose radiation therapy or standard radiation therapy in treating patients with early-stage breast cancer that was removed by surgery. RTOG 1005. 2013 Located at www.cancer.gov/clinicaltrials/seach/view?cdrid=700069, Accessed January 3rd, 2013.